Related Experiment Video
Updated: Nov 16, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
Belén Rodríguez de Castro1, Cristina Martinez-Múgica Barbosa2, Aitor Ayastuy Ruiz2
1Pharmacy Department, Hospital Universitario Cabueñes, Gijón, Spain b.rocas23@gmail.com.
Objective:
To estimate the risk of progressive multifocal leukoencephalopathy (PML) and the safety of natalizumab administration in patients with relapsing-remitting multiple sclerosis (RRMS).
Methods:
A descriptive retrospective observational study including all patients with RRMS treated with natalizumab followed-up after 10 years.The likelihood of developing PML was estimated based on three risk factors: anti-John Cunningham virus antibody index, previous immunosuppressive therapy, and duration of treatment. Patients were classified into five categories: minimum probability (<0.1/1000); low (0.1/1000); medium-low (0.2-0.6/1000); medium-high (0.8-3/1000); high probability (3-10/1000).
Results:
34 patients were included. The probability of PML in the last cycle was: 55.9% minimum, 8.8% low, 11.8% medium-low, 3% medium-high, and 20.5% high. 12 patients continue with active treatment with natalizumab. No cases of PML have been confirmed. Adverse effects were detected in 50% of patients.
Conclusions:
Quantifying risk factors allows us to estimate the probability of PML appearance, thus assessing the maintenance or suspension of natalizumab.
More Related Videos
Related Concept Videos
Relative Risk
Teratogenicity
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Drug Accumulation During Multiple Dosing: Repetitive IV Injections

